Levofloxacin chemical structure
Find information on thousands of medical conditions and prescription drugs.

Levofloxacin

Levofloxacin is a fluoroquinolone antibiotic, marketed by Ortho-McNeil under the brand name Levaquin. Chemically, levofloxacin is the S-enantiomer (L-isomer) of ofloxacin. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Levofloxacin is effective against a number of gram-positive and gram-negative bacteria. Because of its broad spectrum of action, levofloxacin is frequently prescribed empirically for a wide range of infections (e.g. pneumonia, urinary tract infection) before the specific causal organism is known. If the causal organism is identified, levofloxacin is sometimes discontinued and the patient may be switched to an antibiotic with a narrower spectrum

Gram-positive bacteria

  • Enterococcus faecalis (many strains are only moderately susceptible)
  • Staphylococcus aureus (methicillin-susceptible strains)
  • Staphylococcus epidermidis (methicillin-susceptible strains)
  • Staphylococcus saprophyticus
  • Streptococcus pneumoniae (including penicillin-resistant strains*)
  • Streptococcus pyogenes

Levofloxacin only has moderate Gram-positive coverage; beta-lactams (e.g. ceftriaxone) or glycopeptides (e.g. vancomycin) are generally preferred for this indication.

Gram-negative bacteria

  • Enterobacter cloacae
  • Klebsiella pneumoniae
  • Pseudomonas aeruginosa
  • Escherichia coli
  • Legionella pneumophila
  • Serratia marcescens
  • Haemophilus influenzae
  • Moraxella catarrhalis
  • Haemophilus parainfluenzae
  • Proteus mirabilis
  • Campylobacter

Other

  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

Some information extracted from Levaquin Prescribing information.

Read more at Wikipedia.org


[List your site here Free!]


Experimental pleurodesis: intrapleural injection of azythromycin, clarithromycin or levofloxacin
From CHEST, 10/1/05 by Renam U. Bumlai

PURPOSE: Pleurodesis is commonly used to treat recurrent pleural effusion or pueumothorax. The ideal agent for pleurodesis is still being sought. Previous studies demonstrated that intrapleural instillation of erythromycin, a macrolide antibiotic, could be a potential pleural sclerosing agent. There is no studies demonstrating the effect of quinolones as pleural sclerosing. The aim of this study was to evaluate the intrapleural injection of azythromycin, clarithromycin or levofloxacin as pleural sclerosing agents.

METHODS: Thirty rabbits, divided in 3 groups received, through a chest tube, intrapleural administration of azythromycin (15mg/kg), clarithromycin (15 mg/kg) or levofloxacin (10 mg/kg) in a total volume of 2ml. After 28 days the animals were sacrificed and the degree of pleural adhesions were evaluated in a score from 0 (no adhesions) to 4 (complete obliteration of pleural space). Pleurodesis are considered when score >3. We also evaluated the microscopic changes for inflammation and fibrosis in scores from 0 to 4 according to the intensity of process. Statistical analysis: Descriptive Analysis (mean + standard deviation) and Kruskall Wallis ANOVA.

RESULTS: After the intrapleural administration of azythromycin, clarithromycin or levofloxacin we observed a few macroscopic adhesions. The scores were 1.2 [+ or -] 0.5, 1.2 [+ or -] 1.0 and 1.0 [+ or -] 0.5 respectively, and no statistical difference were observed among the groups. The microscopic analysis of pleura and parenchyma showed discrete changes for all drugs, with a greater scores of pleural fibrosis in the clarithromycin group.

CONCLUSION: The intrapleural injection of azythromycin, clarithromycin or levofloxacin was ineffective in creating pleurodesis in our experimental model.

CLINICAL IMPLICATIONS: Macrolides or quint]ones should not be recommended as a pleural sclerosing agent, when a pleurodesis is attempt.

DISCLOSURE: Lisete Teixeira, None.

Renam U. Bumlai Francisco S. Vargas MD Milena M. Acencio BS Leila Antonangelo MD Gabriela G. Carnevale PharmD Evaldo Marchi MD Lisete R. Teixeira MD * Pulmonary Division, Heart Institute (InCor), Sat Paulo Medical School, Sat Paulo, Brazil

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Levofloxacin
Home Contact Resources Exchange Links ebay